The U.S. Patent and Trademark Office has issued a patent on an innovation to improve upon therapeutics that pertain to controlling protein function.
More than two dozen inhibitors of disease-associated enzymes have been developed and approved for clinical use. They are considered invaluable in illuminating the mechanism of these diseases and providing novel therapeutics. But there are challenges to further develop them into potent, selective and drug-like inhibitors.
The IU innovation includes a variety of inhibitors that provide a method that could treat tuberculosis, cancer, Lafora disease and Type 2 diabetes.
The innovation was disclosed to the IU Innovation and Commercialization Office. The mission of the office is to drive innovation to the market for the benefit of the public, the university and innovators for state, national and global commerce. IU personnel can disclose an invention online.